The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.

ABSTRACT:

Background

The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those with HER2-positive tumors that can be treated with anti-HER2 therapy. Therefore, we have sought to identify novel targeted therapies for TNBC. In this study, we investigated the potential of a novel phosphatase, NUDT5, as a potential therapeutic target for TNBC.

Methods

The mRNA expression levels of NUDT5 in breast cancers were investigated using TCGA and METABRIC (Cur

SUBMITTER: Qian J 

PROVIDER: S-EPMC10845800 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature